loading page

Female Oncofertility and Immune Checkpoint Blockade in Melanoma: Where Are We Today?
  • +3
  • Cha Len Lee,
  • Erika Martinez,
  • Diego Gimenez,
  • Thiago Muniz,
  • Marcus Butler,
  • Samuel Saibil
Cha Len Lee
Princess Margaret Hospital Cancer Centre

Corresponding Author:[email protected]

Author Profile
Erika Martinez
Princess Margaret Hospital Cancer Centre
Author Profile
Diego Gimenez
Princess Margaret Hospital Cancer Centre
Author Profile
Thiago Muniz
Princess Margaret Hospital Cancer Centre
Author Profile
Marcus Butler
Princess Margaret Hospital Cancer Centre
Author Profile
Samuel Saibil
Princess Margaret Hospital Cancer Centre
Author Profile

Abstract

The incidence of melanoma among young adults has risen, yet mortality has declined annually since the introduction of immune checkpoint inhibitors (ICI). The utilization of peri-operative ICI has significantly altered the treatment landscape in melanoma, with PD-1 inhibitors showing promising efficacy in improving relapse-free survival rates in high-risk stage II-III disease. With the increasing use of ICI, secondary concerns have emerged regarding the impact of cancer drugs on fertility and reproductive health among child-bearing women, especially in early-stage cancer settings. The exclusion of pregnant women from trials contributes to limited human data and clinical uncertainties, such as maternal and fetal toxicities related to ICI exposure during pregnancy, as well as the value of fertility preservation prior to ICI therapy. Additionally, uncertainty persists regarding pregnancy planning after immunotherapy in an adjuvant setting, given the potential detrimental effects of hormonal and immunological changes during pregnancy on melanoma relapse. These considerations raise questions about whether pregnancy-associated melanoma (PAM) represents a distinct disease entity that warrants tailored management compared to non-pregnant cases.
Submitted to Cancer Reports
16 May 2024Reviewer(s) Assigned
10 Jun 2024Review(s) Completed, Editorial Evaluation Pending
25 Jun 2024Editorial Decision: Revise Major
10 Aug 20241st Revision Received
10 Aug 2024Submission Checks Completed
10 Aug 2024Assigned to Editor
10 Aug 2024Review(s) Completed, Editorial Evaluation Pending
11 Aug 2024Reviewer(s) Assigned